Author Topic: (Abst.) Ovarian aging associated w/gray matter volume [loss] and disability in women w/MS  (Read 69 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9670
  • MS diagnosed 1980
  • Location: Pacific Northwest
From PubMed, December 24, 2017:

Neurology. 2017 Dec 22.

Ovarian aging is associated with gray matter volume [loss] and disability in women with MS

Graves JS1, Henry RG2, Cree BAC2, Lambert-Messerlian G2, Greenblatt RM2, Waubant E2, Cedars MI2, Zhu A2; University of California, San Francisco MS-EPIC Team,, Bacchetti P2, Hauser SL2, Oksenberg JR2.
Collaborators (17)


To determine if ovarian aging as measured by levels of anti-Müllerian hormone (AMH) is associated with pattern of multiple sclerosis (MS) progression in women.


Women with MS and healthy controls were included from a longitudinal research cohort with up to 10 years follow-up. Plasma AMH levels were measured by ELISA for baseline and years 3, 5, and 8-10. Mixed effects logistic and linear regression models were employed, with adjustments for age, disease duration, and other covariables as appropriate.


AMH levels were similar (0.98-fold difference, 95% confidence interval [CI] 0.69-1.37, p = 0.87) in women with MS (n = 412, mean age 42.6 years) and healthy controls (n = 180, mean age 44 years). In a multivariable model of women with MS, including adjustments for age, body mass index, and disease duration, 10-fold lower AMH level was associated with 0.43-higher Expanded Disability Status Scale (EDSS) score (95% CI 0.15-0.70, p = 0.003), 0.25-unit worse MS Functional Composite z score (95% CI -0.40 to -0.10, p = 0.0015), and 7.44 mm3 lower cortical gray matter volume (95% CI -14.6 to -0.30; p = 0.041) at baseline.

In a multivariable random-intercept-random-slope model using all observations over time, 10-fold decrease in AMH was associated with a 0.27 increase in EDSS (95% CI 0.11-0.43, p = 0.006) and 5.48 mm3 (95% CI 11.3-0.33, p = 0.065) and 4.55 mm3 (95% CI 9.33-0.23, p = 0.062) decreases in total gray and cortical gray matter, respectively.


As a marker of ovarian aging, lower AMH levels were associated with greater disability and gray matter loss in women with MS independent of chronological age and disease duration.
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.


Related Topics

  Subject / Started by Replies Last post
0 Replies
Last post April 21, 2016, 04:10:22 pm
by agate
0 Replies
Last post March 16, 2018, 11:51:28 am
by agate
0 Replies
Last post May 28, 2018, 03:40:46 pm
by agate
1 Replies
Last post January 17, 2019, 07:44:54 am
by agate
0 Replies
Last post December 18, 2021, 08:51:29 pm
by agate